Cutera Stock Forecast, Price & News

-1.64 (-3.31 %)
(As of 09/16/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume133,638 shs
Average Volume214,315 shs
Market Capitalization$859.06 million
P/E Ratio133.00
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CUTR News and Ratings via Email

Sign-up to receive the latest news and ratings for Cutera and its competitors with MarketBeat's FREE daily newsletter.

Cutera logo

About Cutera

Cutera, Inc. engages in the provision of laser and energy-based aesthetic systems for practitioners. It operates through the following segments: United States, Japan, Asia excluding Japan, Europe, and Rest of the World. Its products include enlighten, excel HR, excel V+, secret Pro, Juliet, secret RF, and xeo. The company was founded by David A. Gollnick in August 1998 and is headquartered in Brisbane, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.31 out of 5 stars

Computer And Technology Sector

219th out of 857 stocks

Electromedical Equipment Industry

4th out of 31 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Cutera (NASDAQ:CUTR) Frequently Asked Questions

Is Cutera a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cutera in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cutera stock.
View analyst ratings for Cutera
or view top-rated stocks.

What stocks does MarketBeat like better than Cutera?

Wall Street analysts have given Cutera a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cutera wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cutera's next earnings date?

Cutera is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Cutera

How were Cutera's earnings last quarter?

Cutera, Inc. (NASDAQ:CUTR) released its earnings results on Wednesday, August, 4th. The medical device company reported $0.39 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.49. The medical device company earned $58.59 million during the quarter, compared to the consensus estimate of $50.15 million. Cutera had a net margin of 3.71% and a trailing twelve-month return on equity of 14.36%.
View Cutera's earnings history

How has Cutera's stock price been impacted by COVID-19 (Coronavirus)?

Cutera's stock was trading at $18.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CUTR shares have increased by 164.4% and is now trading at $47.88.
View which stocks have been most impacted by COVID-19

What guidance has Cutera issued on next quarter's earnings?

Cutera updated its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $215 million-$221 million, compared to the consensus revenue estimate of $205.73 million.

What price target have analysts set for CUTR?

2 analysts have issued 12-month target prices for Cutera's shares. Their forecasts range from $60.00 to $65.00. On average, they expect Cutera's stock price to reach $62.50 in the next twelve months. This suggests a possible upside of 30.5% from the stock's current price.
View analysts' price targets for Cutera
or view top-rated stocks among Wall Street analysts.

Who are Cutera's key executives?

Cutera's management team includes the following people:
  • David H. Mowry, Chief Executive Officer & Director
  • Rohan Seth, Chief Financial Officer
  • Michael Karavitis, Chief Technology Officer & Executive VP
  • Jeremy Livianu, Secretary, Vice President & General Counsel
  • Anne Werdan, Director-Investor Relations

What is David H. Mowry's approval rating as Cutera's CEO?

1 employees have rated Cutera CEO David H. Mowry on David H. Mowry has an approval rating of 100% among Cutera's employees. This puts David H. Mowry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Cutera's key competitors?

What other stocks do shareholders of Cutera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cutera investors own include NVIDIA (NVDA), QUALCOMM (QCOM), AbbVie (ABBV), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), DocuSign (DOCU), Pfizer (PFE), Square (SQ) and Twilio (TWLO).

What is Cutera's stock symbol?

Cutera trades on the NASDAQ under the ticker symbol "CUTR."

Who are Cutera's major shareholders?

Cutera's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.04%), Gamco Investors INC. ET AL (6.94%), Vanguard Group Inc. (6.24%), First Light Asset Management LLC (5.67%), RTW Investments LP (4.02%) and State Street Corp (3.88%). Company insiders that own Cutera stock include David H Mowry, J Daniel Plants, Joseph E Whitters and Katherine S Zanotti.
View institutional ownership trends for Cutera

Which institutional investors are selling Cutera stock?

CUTR stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, First Light Asset Management LLC, The Manufacturers Life Insurance Company , BlackRock Inc., Essex Investment Management Co. LLC, Russell Investments Group Ltd., Kennedy Capital Management Inc., and Gabelli Funds LLC.
View insider buying and selling activity for Cutera
or view top insider-selling stocks.

Which institutional investors are buying Cutera stock?

CUTR stock was purchased by a variety of institutional investors in the last quarter, including RTW Investments LP, Paradigm Capital Management Inc. NY, Bank of Montreal Can, Royal Bank of Canada, Invesco Ltd., Lisanti Capital Growth LLC, Deutsche Bank AG, and Morgan Stanley. Company insiders that have bought Cutera stock in the last two years include David H Mowry, J Daniel Plants, Joseph E Whitters, and Katherine S Zanotti.
View insider buying and selling activity for Cutera
or or view top insider-buying stocks.

How do I buy shares of Cutera?

Shares of CUTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cutera's stock price today?

One share of CUTR stock can currently be purchased for approximately $47.88.

How much money does Cutera make?

Cutera has a market capitalization of $859.06 million and generates $147.68 million in revenue each year. The medical device company earns $-23,880,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

How many employees does Cutera have?

Cutera employs 323 workers across the globe.

When was Cutera founded?

Cutera was founded in 1998.

What is Cutera's official website?

The official website for Cutera is

Where are Cutera's headquarters?

Cutera is headquartered at 3240 BAYSHORE BOULEVARD, BRISBANE CA, 94005.

How can I contact Cutera?

Cutera's mailing address is 3240 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The medical device company can be reached via phone at (415) 657-5500 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.